CDIO — Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ Capital Market
• Employees: 13
• Website: https://cardiodiagnosticsinc.com

Latest SEC filings for CDIO

• 10-Q — 2026-05-15
• 10-K — 2026-03-13
• 10-Q — 2025-11-12
• 8-K — 2025-10-15
• 424B3 — 2025-09-23
• 424B3 — 2025-09-12
• 10-Q — 2025-08-14
• 8-K — 2025-05-28
• 10-Q — 2025-05-15
• 8-K — 2025-05-13

Abrir análisis completo

Educational tool only — not investment advice.